Pharmacy Faculty & Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Future Oncol. 2013 Jan;9(1):59-68. doi: 10.2217/fon.12.171.
Nanoparticle-based gene delivery systems may be more efficient for administration of therapeutic genes to solid tumors and cancer metastases, owing to the numerous advantages in terms of enhanced tissue penetrability, improved cellular uptake and targeted gene delivery to the cells of interest compared with other gene delivery systems. Intraperitoneal (IP) delivery of therapeutic agents offers special merits because of the anatomical situation of peritoneum for local cancer therapy. Via the IP administration route, it is possible to target the therapeutic agents exactly to the target cells and protect healthy tissues outside the peritoneal cavity from side effects. IP delivery could be applicable for the treatment of disorders of organs in the peritoneal cavity covered with peritoneum and subperitoneal connective tissue, including cancers such as ovarian and gastric. The goal of this article is to review the current state of IP delivery of nanoparticles for cancer gene therapy.
基于纳米粒子的基因传递系统可能更有效地将治疗基因递送至实体瘤和癌症转移灶，因为与其他基因传递系统相比，其具有增强的组织穿透性、改善的细胞摄取能力和靶向递送至感兴趣细胞的优势。与其他基因传递系统相比，腹腔内（IP）递送来治疗剂具有特殊的优点，因为腹膜的解剖结构适用于局部癌症治疗。通过 IP 给药途径，可以将治疗剂精确地靶向到靶细胞，并保护腹腔外的健康组织免受副作用的影响。IP 给药可能适用于治疗腹膜覆盖的腹腔内器官和腹膜下结缔组织的疾病，包括卵巢癌和胃癌等癌症。本文的目的是综述目前用于癌症基因治疗的 IP 递纳米粒子的现状。
